MUCIN-4 (MUC4) is a novel tumor antigen in pancreatic cancer immunotherapy.

[1]  Sara R. Selitsky,et al.  Machine-Learning Prediction of Tumor Antigen Immunogenicity in the Selection of Therapeutic Epitopes , 2019, Cancer Immunology Research.

[2]  Jia Wei,et al.  Tumor neoantigens: from basic research to clinical applications , 2019, Journal of Hematology & Oncology.

[3]  R. Steinman,et al.  Anti–CTLA‐4 synergizes with dendritic cell–targeted vaccine to promote IL‐3–dependent CD4+ effector T cell infiltration into murine pancreatic tumors , 2019, Annals of the New York Academy of Sciences.

[4]  E. Jaffee,et al.  Current Status of Immunotherapies for Treating Pancreatic Cancer , 2019, Current Oncology Reports.

[5]  B. O'Neil,et al.  Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study , 2019, BMC Cancer.

[6]  Jia Wei,et al.  Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. , 2019, The Journal of clinical investigation.

[7]  V. Balachandran,et al.  Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities. , 2019, Gastroenterology.

[8]  T. Andl,et al.  Cancer-Associated Fibroblasts Build and Secure the Tumor Microenvironment , 2019, Front. Cell Dev. Biol..

[9]  C. Mai,et al.  Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment , 2019, Journal of Experimental & Clinical Cancer Research.

[10]  S. Batra,et al.  Amphiphilic polyanhydride-based recombinant MUC4β-nanovaccine activates dendritic cells , 2019, Genes & cancer.

[11]  M. Block,et al.  The evolving clinical landscape for dendritic cell vaccines and cancer immunotherapy. , 2019, Immunotherapy.

[12]  P. Soon-Shiong,et al.  NANT cancer vaccine an orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T cell therapy in patients with third line or greater metastatic pancreatic cancer. , 2019, Journal of Clinical Oncology.

[13]  J. Gartner,et al.  Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients , 2019, Nature Communications.

[14]  C. Iacobuzio-Donahue,et al.  Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer , 2019, Proceedings of the National Academy of Sciences.

[15]  I. Endo,et al.  Role of the tumor microenvironment in pancreatic cancer , 2019, Annals of gastroenterological surgery.

[16]  Jinha M. Park,et al.  Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer , 2018, British Journal of Cancer.

[17]  Quanbo Zhou,et al.  Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer , 2018, Cell Death & Disease.

[18]  E. Jaffee,et al.  Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer. , 2018, JCI insight.

[19]  S. Hanada,et al.  Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with WT1-targeted dendritic cell vaccines , 2018, Human vaccines & immunotherapeutics.

[20]  H. Nagano,et al.  Combination treatment of advanced pancreatic cancer using novel vaccine and traditional therapies , 2018, Expert Review of Anticancer Therapy.

[21]  S. Wiemann,et al.  Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses , 2018, Oncoimmunology.

[22]  Bjoern Peters,et al.  Predicting T cell recognition of MHC class I restricted neoepitopes , 2018, Oncoimmunology.

[23]  H. Algül,et al.  Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options , 2018, Front. Immunol..

[24]  Lynette M. Smith,et al.  Axed MUC4 (MUC4/X) aggravates pancreatic malignant phenotype by activating integrin-β1/FAK/ERK pathway. , 2018, Biochimica et biophysica acta. Molecular basis of disease.

[25]  C. Neuzillet,et al.  Immune therapies in pancreatic ductal adenocarcinoma: Where are we now? , 2018, World journal of gastroenterology.

[26]  J. Taylor‐Papadimitriou,et al.  Latest developments in MUC1 immunotherapy , 2018, Biochemical Society transactions.

[27]  J. Kleeff,et al.  Therapeutic developments in pancreatic cancer: current and future perspectives , 2018, Nature Reviews Gastroenterology & Hepatology.

[28]  S. Batra,et al.  Emerging trends in the immunotherapy of pancreatic cancer. , 2018, Cancer letters.

[29]  P. Singh,et al.  Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors , 2018, Cancer Immunology, Immunotherapy.

[30]  Astrid Gall,et al.  Ensembl 2018 , 2017, Nucleic Acids Res..

[31]  Mithat Gönen,et al.  Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer , 2017, Nature.

[32]  Steven J. M. Jones,et al.  Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. , 2017, Cancer cell.

[33]  H. Sugiyama,et al.  Significance of Wilms' tumor 1 antigen as a cancer vaccine for pancreatic cancer. , 2017, Discovery medicine.

[34]  M. Oka,et al.  Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy , 2017, Pancreas.

[35]  S. Batra,et al.  MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma , 2017, Expert opinion on therapeutic targets.

[36]  Hans Clevers,et al.  Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer , 2017, The Journal of experimental medicine.

[37]  J. Nilsson,et al.  Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine , 2017, Scandinavian journal of gastroenterology.

[38]  S. Batra,et al.  Genetic variants of mucins: unexplored conundrum , 2016, Carcinogenesis.

[39]  S. Ormanns,et al.  Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer. , 2016, Cancer letters.

[40]  Lynette M. Smith,et al.  MUC16 contributes to the metastasis of pancreatic ductal adenocarcinoma through focal adhesion mediated signaling mechanism , 2016, Genes & cancer.

[41]  Lynette M. Smith,et al.  The canonical Wnt pathway regulates the metastasis‐promoting mucin MUC4 in pancreatic ductal adenocarcinoma , 2016, Molecular oncology.

[42]  S. Batra,et al.  Understanding the Unique Attributes of MUC16 (CA125): Potential Implications in Targeted Therapy. , 2015, Cancer Research.

[43]  E. Jaffee,et al.  Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  E. Schmitt,et al.  Antibody Induction Directed against the Tumor‐Associated MUC4 Glycoprotein , 2015, Chembiochem : a European journal of chemical biology.

[45]  E. Furth,et al.  Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma , 2015, Cancer Immunology Research.

[46]  E. Jaffee,et al.  PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors , 2015, Journal of immunotherapy.

[47]  Y. Kato.  [Efficacy of WT1 peptide-/MUC-1 peptide-pulsed dendritic cell therapy in 313 patients with a wide range of cancers]. , 2014, Gan to kagaku ryoho. Cancer & chemotherapy.

[48]  Y. Yen,et al.  p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses , 2014, Clinical Cancer Research.

[49]  R. Hruban,et al.  Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation , 2014, Cancer Immunology Research.

[50]  R. Sainson,et al.  Regulation of the anti-tumour immune response by cancer-associated fibroblasts. , 2014, Seminars in cancer biology.

[51]  S. Batra,et al.  Mucins in pancreatic cancer and its microenvironment , 2013, Nature Reviews Gastroenterology &Hepatology.

[52]  Xu Liu,et al.  Generation of CTL responses against pancreatic cancer in vitro using dendritic cells co-transfected with MUC4 and survivin RNA. , 2013, Vaccine.

[53]  L. De Monte,et al.  Immune infiltrates as predictive markers of survival in pancreatic cancer patients , 2013, Front. Physiol..

[54]  K. Konstantopoulos,et al.  Mesothelin Binding to CA125/MUC16 Promotes Pancreatic Cancer Cell Motility and Invasion via MMP-7 Activation , 2013, Scientific Reports.

[55]  M. Büchler,et al.  Advanced-stage pancreatic cancer: therapy options , 2013, Nature Reviews Clinical Oncology.

[56]  T. Welling,et al.  T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. , 2013, Current opinion in immunology.

[57]  S. Batra,et al.  Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: potential implications for diagnosis and therapy , 2012, Journal of Hematology & Oncology.

[58]  Judy M. Anderson,et al.  Pathobiological Implications of MUC16 Expression in Pancreatic Cancer , 2011, PloS one.

[59]  S. Batra,et al.  Monoclonal Antibodies Recognizing the Non-Tandem Repeat Regions of the Human Mucin MUC4 in Pancreatic Cancer , 2011, PloS one.

[60]  S. Batra,et al.  MUC4 stabilizes HER2 expression and maintains the cancer stem cell population in ovarian cancer cells , 2011, Journal of ovarian research.

[61]  Marc D Porter,et al.  Detection of the potential pancreatic cancer marker MUC4 in serum using surface-enhanced Raman scattering. , 2011, Analytical chemistry.

[62]  S. Batra,et al.  Novel Interaction of MUC4 and Galectin: Potential Pathobiological Implications for Metastasis in Lethal Pancreatic Cancer , 2010, Clinical Cancer Research.

[63]  I. van Seuningen,et al.  Mucins and Pancreatic Cancer , 2010, Cancers.

[64]  S. Gendler,et al.  MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition , 2010, Oncogene.

[65]  M. Moore,et al.  Advanced pancreatic carcinoma: current treatment and future challenges , 2010, Nature Reviews Clinical Oncology.

[66]  D. Kufe,et al.  Mucins in cancer: function, prognosis and therapy , 2009, Nature Reviews Cancer.

[67]  S. Batra,et al.  Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin , 2009, British Journal of Cancer.

[68]  Y. Miao,et al.  Identification of an HLA-A*0201-restrictive CTL epitope from MUC4 for applicable vaccine therapy , 2009, Immunopharmacology and immunotoxicology.

[69]  I. C. Leão,et al.  Effective Depletion of Regulatory T Cells Allows the Recruitment of Mesothelin‐Specific CD8+ T Cells to the Antitumor Immune Response Against a Mesothelin‐Expressing Mouse Pancreatic Adenocarcinoma , 2008, Clinical and translational science.

[70]  J. Meza,et al.  MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells (Cancer Research (April 1, 2008) 68(2065-2070)) , 2008 .

[71]  J. Meza,et al.  MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. , 2008, Cancer research.

[72]  Y. Miao,et al.  Dendritic cells expressing a combined PADRE/MUC4-derived polyepitope DNA vaccine induce multiple cytotoxic T-cell responses. , 2008, Cancer biotherapy & radiopharmaceuticals.

[73]  Morten Nielsen,et al.  Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction , 2007, BMC Bioinformatics.

[74]  P. Chaturvedi,et al.  Human MUC4 mucin induces ultra-structural changes and tumorigenicity in pancreatic cancer cells , 2007, British Journal of Cancer.

[75]  D. Goldenberg,et al.  New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  S. Batra,et al.  MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas , 2005, Journal of Clinical Pathology.

[77]  S. Batra,et al.  Generation and Characterization of Anti-MUC4 Monoclonal Antibodies Reactive with Normal and Cancer Cells in Humans , 2004, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[78]  J. Meza,et al.  Inhibition of MUC4 Expression Suppresses Pancreatic Tumor Cell Growth and Metastasis , 2004, Cancer Research.

[79]  T. Oshikiri,et al.  CD8+ Tumor-Infiltrating Lymphocytes Together with CD4+ Tumor-Infiltrating Lymphocytes and Dendritic Cells Improve the Prognosis of Patients with Pancreatic Adenocarcinoma , 2004, Pancreas.

[80]  J. Meza,et al.  Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. , 2003, Cancer research.

[81]  J. Cameron,et al.  MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. , 2002, American journal of clinical pathology.

[82]  M. Hollingsworth,et al.  Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti‐adhesion molecule , 2000, International journal of cancer.

[83]  I. G. Glitza Oliva,et al.  Immunotherapy for Melanoma. , 2020, Advances in experimental medicine and biology.

[84]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[85]  I. G. Glitza Oliva,et al.  Immunotherapy for Melanoma. , 2018, Advances in experimental medicine and biology.

[86]  Lynette M. Smith,et al.  A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study , 2017, The American Journal of Gastroenterology.

[87]  Zhiwei Wang,et al.  Pancreatic cancer: understanding and overcoming chemoresistance , 2011, Nature Reviews Gastroenterology &Hepatology.